Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [31] Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
    Maggi, P
    Serio, G
    Epifani, G
    Fiorentino, G
    Saracino, A
    Fico, C
    Perilli, F
    Lillo, A
    Ferraro, S
    Gargiulo, M
    Chirianni, A
    Angarano, G
    Regina, G
    Pastore, G
    AIDS, 2000, 14 (16) : F123 - F128
  • [32] Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure
    van Zoest, Rosan A.
    Wit, Ferdinand W.
    Kooij, Katherine W.
    van der Valk, Marc
    Schouten, Judith
    Kootstra, Neeltje A.
    Wiersinga, W. Joost
    Prins, Maria
    van den Born, Bert-Jan H.
    Reiss, Peter
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (02) : 205 - 213
  • [33] Survival in HIV-1 patients receiving antiretroviral therapy in Morocco
    Titou, H.
    Baba, N.
    Kasouati, J.
    Oumakir, S.
    Frikh, R.
    Boui, M.
    Hjira, N.
    REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2018, 66 (05): : 310 - 315
  • [34] Evaluation of a 6-Year Highly Active Antiretroviral Therapy in Chinese HIV-1-Infected Patients
    Zhou, Hua-ying
    Zheng, Yu-huang
    He, Yan
    Chen, Zi
    Liu, Meng
    Yin, Wei
    Liu, Chun
    INTERVIROLOGY, 2010, 53 (04) : 240 - 246
  • [35] Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study
    Lo, Y-C
    Chen, M-Y
    Sheng, W-H
    Hsieh, S-M
    Sun, H-Y
    Liu, W-C
    Wu, P-Y
    Wu, C-H
    Hung, C-C
    Chang, S-C
    HIV MEDICINE, 2009, 10 (05) : 302 - 309
  • [36] Cardiovascular risks in Asian HIV-infected patients receiving boosted- protease inhibitor-based antiretroviral treatment
    Ounjaijean, Sakaewan
    Kulprachakarn, Kanokwan
    Aurpibul, Linda
    Kaewpoowat, Quanhathai
    Boonyapranai, Kongsak
    Chaiwarith, Romanee
    Arwon, Supapong
    Supparatpinyo, Khuanchai
    Rerkasem, Kittipan
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (02): : 289 - 296
  • [37] Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens
    Ferretti, Francesca
    Mackie, Nicola E.
    Singh, Gurmit Kaur Jagjit
    Fox, Julie
    Kaye, Steve
    McClure, Myra O.
    Taylor, Graham
    Boffito, Marta
    HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 107 - 110
  • [38] Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
    Grabar, S
    Pradier, C
    Le Corfec, E
    Lancar, R
    Allavena, C
    Bentata, M
    Berlureau, P
    Dupont, C
    Fabbro-Peray, P
    Poizot-Martin, I
    Costagliola, D
    AIDS, 2000, 14 (02) : 141 - 149
  • [39] Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-Specific protease inhibitor ritonavir
    Tepper, VJ
    Farley, JJ
    Rothman, MI
    Houck, DL
    Davis, KF
    Collins-Jónes, TL
    Wachtel, RC
    PEDIATRICS, 1998, 101 (03) : E7
  • [40] Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
    Casado, JL
    Perez-Elías, MJ
    Antela, A
    Sabido, R
    Martí-Belda, P
    Dronda, F
    Blazquez, J
    Quereda, C
    AIDS, 1998, 12 (11) : F131 - F135